TMCnet News
Global Hypertrophic Cardiomyopathy Therapeutics Market to Grow at a CAGR of 1.8%, 2017-2021 with AstraZeneca, Merck, Pfizer & Sanofi Dominating - Research and MarketsResearch and Markets has announced the addition of the "Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021" report to their offering. The global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021. The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. One trend in market is development of TBI. HCM is a complex genetic disorder, which requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed in order to enhance the clinical guidelines for treatment and prevention of HCM ad are named as TBI. TBI is a computational approach, which focuses on the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source, which not only performs data integration but also improves data representation. This will be done by using tools such as ontology and controlled vocabulary, as they provide a standard way for representation of data. These vocabulary sources are references that are accepted by specific user community like Gene Ontology (News - Alert) and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT). Key vendors
Other Prominent Vendors
Key Topics Covered: PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction PART 05: Disease overview PART 06: Key clinical trials PART 07: Market dynamics PART 08: Market landscape PART 09: Market segmentation by drug-class PART 10: Geographical segmentation PART 11: Decision framework PART 12: Drivers and challenges PART 13: Market trends PART 14: Vendor landscape PART 15: Key vendor analysis PART 16: Appendix For more information about this report visit http://www.researchandmarkets.com/research/vtws8x/global View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005779/en/ |